Skip to content
Viroptic, Lonsurf(trifluridine)
Lonsurf, Viroptic (trifluridine) is a small molecule pharmaceutical. Trifluridine was first approved as Viroptic on 1982-01-01. It is used to treat herpetic keratitis, infectious keratoconjunctivitis, and virus diseases in the USA. It has been approved in Europe to treat colorectal neoplasms.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
neoplasmsD009369
digestive system diseasesD004066
eye diseasesD005128
animal diseasesD000820
Trade Name
FDA
EMA
Viroptic (generic drugs available since 1995-10-06)
Combinations
Lonsurf
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Tipiracil hydrochloride
+
Trifluridine
Tradename
Company
Number
Date
Products
LONSURFTaiho OncologyN-207981 RX2015-09-22
2 products, RLD, RS
Trifluridine
Tradename
Company
Number
Date
Products
VIROPTICMonarch PharmaceuticalsN-018299 RX1982-01-01
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
lonsurfNew Drug Application2020-01-14
trifluridineANDA2021-08-05
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
herpetic keratitisEFO_0007308D016849
infectious keratoconjunctivitisD007639
virus diseasesD014777B34
Agency Specific
FDA
EMA
Expiration
Code
TIPIRACIL HYDROCHLORIDE / TRIFLURIDINE, LONSURF, TAIHO ONCOLOGY
2026-02-22ODE-229
Patent Expiration
Patent
Expires
Flag
FDA Information
Tipiracil Hydrochloride / Trifluridine, Lonsurf, Taiho Oncology
104563992037-02-03U-2642
109600042037-02-03U-2642
95278332034-06-17DS, DP
104576662034-06-17DS, DP
RE462842029-09-22U-1751, U-2503
ATC Codes
L: Antineoplastic and immunomodulating agents
L01: Antineoplastic agents
L01B: Antimetabolites
L01BC: Pyrimidine analogues, antineoplastic antimetabolites
L01BC59: Trifluridine, combinations
S: Sensory organ drugs
S01: Ophthalmologicals
S01A: Antiinfective ophthalmologics
S01AD: Antivirals, ophthalmologic
S01AD02: Trifluridine
HCPCS
No data
Clinical
Clinical Trials
109 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD015179173115358
NeoplasmsD009369C8091110
Stomach neoplasmsD013274EFO_0003897C161516
Neoplasm metastasisD009362EFO_0009708111
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AdenocarcinomaD00023038111
Colonic neoplasmsD003110C18268
Rectal neoplasmsD012004448
Renal cell carcinomaD002292336
Pancreatic neoplasmsD010190EFO_0003860C25245
CholangiocarcinomaD018281C22.133
Breast neoplasmsD001943EFO_0003869C50213
Bile duct neoplasmsD00165022
Gallbladder neoplasmsD005706EFO_0004606C2322
Small cell lung carcinomaD05575211
Show 5 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Gastrointestinal stromal tumorsD046152EFO_0000505C49.A11
Neuroendocrine tumorsD018358EFO_1001901D3A.811
Pancreatic ductal carcinomaD02144111
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B2022
Herpes simplexD006561B0011
Mycobacterium avium-intracellulare infectionD015270EFO_000738611
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTRIFLURIDINE
INNtrifluridine
Description
Trifluridine is a pyrimidine 2'-deoxyribonucleoside compound having 5-trifluoromethyluracil as the nucleobase. An antiviral drug used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis. It has a role as an antiviral drug, an antimetabolite, an EC 2.1.1.45 (thymidylate synthase) inhibitor and an antineoplastic agent. It is a nucleoside analogue, an organofluorine compound and a pyrimidine 2'-deoxyribonucleoside.
Classification
Small molecule
Drug classantivirals; antineoplastics (uridine derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1C(F)(F)F
Identifiers
PDB
CAS-ID70-00-8
RxCUI10803
ChEMBL IDCHEMBL1129
ChEBI ID75179
PubChem CID6256
DrugBankDB00432
UNII IDRMW9V5RW38 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,669 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,716 adverse events reported
View more details